发布求助
文献互助 智能选刊 最新文献

CNS Oncology最新文献

筛选
英文 中文
Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma 氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在原发性中枢神经系统淋巴瘤患者的诊断和分期评估中的应用
CNS Oncology Pub Date : 2019-11-29 DOI: 10.2217/cns-2019-0016
Meetakshi Gupta, T. Gupta, N. Purandare, V. Rangarajan, A. Puranik, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, A. Mahajan, A. Janu, B. Bagal, H. Menon, S. Kannan, R. Krishnatry, G. Sastri, R. Jalali
{"title":"Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma","authors":"Meetakshi Gupta, T. Gupta, N. Purandare, V. Rangarajan, A. Puranik, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, A. Mahajan, A. Janu, B. Bagal, H. Menon, S. Kannan, R. Krishnatry, G. Sastri, R. Jalali","doi":"10.2217/cns-2019-0016","DOIUrl":"https://doi.org/10.2217/cns-2019-0016","url":null,"abstract":"Aim: To prospectively assess the clinical utility of pretreatment flouro-deoxy-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with primary central nervous system (CNS) lymphoma (PCNSL). Materials & methods: Patients with suspected/proven PCNSL underwent baseline whole-body 18F-FDG-PET/CT. Maximum standardized uptake value and tumor/normal tissue ratios were compared between CNS lymphoma and other histological diagnoses. Results: The mean maximum standardized uptake value (27.5 vs 18.2; p = 0.001) and mean tumor/normal tissue ratio (2.34 vs 1.53; p < 0.001) of CNS lymphoma was significantly higher than other histologic diagnoses. Five of 50 (10%) patients with biopsy-proven CNS lymphomas had pathologically increased FDG-uptake at extraneuraxial sites uncovering systemic lymphoma. Conclusion: Pretreatment whole-body 18F-FDG-PET/CT provides valuable complementary information in the diagnostic and staging evaluation of patients with PCNSL to guide therapeutic decision-making.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89693127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
The role of chemotherapy in the treatment of central neurocytoma 化疗在中枢神经细胞瘤治疗中的作用
CNS Oncology Pub Date : 2019-11-01 DOI: 10.2217/cns-2019-0012
Margaret O Johnson, J. Kirkpatrick, Mallika P. Patel, A. Desjardins, D. Randazzo, H. Friedman, D. Ashley, K. Peters
{"title":"The role of chemotherapy in the treatment of central neurocytoma","authors":"Margaret O Johnson, J. Kirkpatrick, Mallika P. Patel, A. Desjardins, D. Randazzo, H. Friedman, D. Ashley, K. Peters","doi":"10.2217/cns-2019-0012","DOIUrl":"https://doi.org/10.2217/cns-2019-0012","url":null,"abstract":"Aim: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. Patients & methods: An institutional review board-approved, chart review of patients seen at our institution resulted in a single case treated with chemotherapy and is herein included. We proceeded with a comprehensive literature review. Results: We identified 18 citations, representing 39 cases of adult and pediatric CN treated with chemotherapy. With the addition of our single case, the total number of recurrent CN patients treated with temozolomide (TMZ) is nine. Conclusion: There exists marked heterogeneity in chemotherapy used to treat CN. TMZ is incorporated into treatment regimens in the setting of tumor recurrence: its role merits further study.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84966989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy 高级别胶质瘤的生物瘤内治疗第二部分:载体和细胞为基础的治疗和放射免疫治疗
CNS Oncology Pub Date : 2019-11-01 DOI: 10.2217/cns-2019-0002
J. Loya, Charlie Zhang, Emily J Cox, A. Achrol, S. Kesari
{"title":"Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy","authors":"J. Loya, Charlie Zhang, Emily J Cox, A. Achrol, S. Kesari","doi":"10.2217/cns-2019-0002","DOIUrl":"https://doi.org/10.2217/cns-2019-0002","url":null,"abstract":"Management of high-grade gliomas (HGGs) remains a complex challenge with an overall poor prognosis despite aggressive multimodal treatment. New translational research has focused on maximizing tumor cell eradication through improved tumor cell targeting while minimizing collateral systemic side effects. In particular, biological intratumoral therapies have been the focus of novel translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two part review will provide an overview of biological intratumoral therapies that have been evaluated in human clinical trials in HGGs, and summarize key advances and remaining challenges in the development of these therapies as a potential new paradigm in the management of HGGs. Part II discusses vector-based therapies, cell-based therapies and radioimmunotherapy.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87345475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins 高级别胶质瘤的生物瘤内治疗第一部分:瘤内输送和免疫毒素
CNS Oncology Pub Date : 2019-11-01 DOI: 10.2217/cns-2019-0001
J. Loya, Charlie Zhang, Emily J Cox, A. Achrol, S. Kesari
{"title":"Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins","authors":"J. Loya, Charlie Zhang, Emily J Cox, A. Achrol, S. Kesari","doi":"10.2217/cns-2019-0001","DOIUrl":"https://doi.org/10.2217/cns-2019-0001","url":null,"abstract":"Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to develop novel therapeutic strategies that can maximize tumor cell eradication while minimizing collateral side effects. Particularly, biological intratumoral therapies have been the focus of new translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two-part review will provide an overview of biological intratumoral therapies and summarize key advances and remaining challenges in intratumoral biological therapies for high-grade glioma. Part I focuses on discussion of the concepts of intratumoral delivery and immunotoxin therapies.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84785003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Prediagnostic presentations of glioma in primary care: a case–control study 初级保健中胶质瘤的诊断前表现:一项病例对照研究
CNS Oncology Pub Date : 2019-11-01 DOI: 10.2217/cns-2019-0015
Marthe C. M. Peeters, L. Dirven, J. Koekkoek, M. Numans, M. Taphoorn
{"title":"Prediagnostic presentations of glioma in primary care: a case–control study","authors":"Marthe C. M. Peeters, L. Dirven, J. Koekkoek, M. Numans, M. Taphoorn","doi":"10.2217/cns-2019-0015","DOIUrl":"https://doi.org/10.2217/cns-2019-0015","url":null,"abstract":"Aim: This study aimed to assess the prevalence of symptoms glioma patients may present with to the general practitioner, and whether these can be distinguished from patients with other CNS disorders or any other condition. Methods: Glioma patients were matched to CNS patients and ‘other controls’ using anonymized general practitioner registries. Prevalences were evaluated in the 5 years prior to diagnosis. Result: CNS patients reported significantly more motor symptoms in the period 60–24 months, (p = 0.039). Moreover, <6 months before diagnosis CNS patients differed significantly in mood disorders/fear compared with ‘other controls’ (p = 0.012) but not glioma patients (p = 0.816). Conclusion: Glioma patients could not be distinguished from both control groups with respect to the number or type of prediagnostic symptoms.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84070153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Hemophagocytic lymphohistiocytosis in a patient with glioblastoma: a case report 胶质母细胞瘤患者的噬血细胞淋巴组织细胞增多症1例报告
CNS Oncology Pub Date : 2019-07-03 DOI: 10.2217/cns-2019-0013
Vaibhav Kumar, Patrick J. Eulitt, A. Bermudez, S. Khagi
{"title":"Hemophagocytic lymphohistiocytosis in a patient with glioblastoma: a case report","authors":"Vaibhav Kumar, Patrick J. Eulitt, A. Bermudez, S. Khagi","doi":"10.2217/cns-2019-0013","DOIUrl":"https://doi.org/10.2217/cns-2019-0013","url":null,"abstract":"Adult onset hemophagocytic lymphohistiocytosis (HLH) is a rare condition, usually secondary to either a precipitating infective or hematologic malignancy. We present a case of Epstein–Barr virus associated HLH in a 55-year-old female receiving treatment for a glioblastoma (GBM). It is possible that HLH is under recognized, as patients with GBM often have features of a nonspecific systemic inflammatory response syndrome, multiorgan failure and cognitive decline. A high index of suspicion and increased awareness can help improve timeliness of diagnosis. Therapeutically, Epstein–Barr virus associated HLH in patients with solid organ malignancy poses significant challenges. An individualized, multidisciplinary approach is essential when managing adult-onset HLH and providers will need to be mindful of the high mortality rate despite treatment.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"45 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2019-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72459642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series 用酪氨酸激酶抑制剂治疗egfr突变的非小细胞肺癌患者的轻脑膜疾病的影像学表现:一个病例系列
CNS Oncology Pub Date : 2019-06-20 DOI: 10.2217/cns-2019-0010
Ugur T Sener, Nassim Matin, H. Yu, A. Lin, T. Yang, R. Malani
{"title":"Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series","authors":"Ugur T Sener, Nassim Matin, H. Yu, A. Lin, T. Yang, R. Malani","doi":"10.2217/cns-2019-0010","DOIUrl":"https://doi.org/10.2217/cns-2019-0010","url":null,"abstract":"EGFR is frequently mutated in non-small-cell lung carcinomas (NSCLCs). Clinically available tyrosine kinase inhibitors (TKIs) are effective in treating EGFR-mutant NSCLC. In this case series, we present five patients with TKI-treated EGFR-mutated NSCLC who developed leptomeningeal disease (LMD) lacking characteristic imaging findings. All five patients received TKIs prior to development of cytology-confirmed LMD. Clinical signs of LMD preceded radiographic evidence by 2–12 months. T790M, the most common resistance mutation to first-generation EGFR inhibitors, was identified in four cases. These cases illustrate that in patients with EGFR-mutant NSCLC, TKIs may effectively control LMD, creating a lag between onset of symptoms and observation of radiographic findings.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89427591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. 419例胶质母细胞瘤及其他原发性脑肿瘤患者游离循环肿瘤DNA分析。
CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-03-11 DOI: 10.2217/cns-2018-0015
David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, Najee Boucher, Garni Barkhoudarian, Daniel F Kelly, Tiffany Juarez, Richard B Lanman, Victoria M Raymond, Minhdan Nguyen, Judy D Truong, Annie Heng, Jaya Gill, Marlon Saria, Sandeep C Pingle, Santosh Kesari
{"title":"Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.","authors":"David E Piccioni,&nbsp;Achal Singh Achrol,&nbsp;Lesli A Kiedrowski,&nbsp;Kimberly C Banks,&nbsp;Najee Boucher,&nbsp;Garni Barkhoudarian,&nbsp;Daniel F Kelly,&nbsp;Tiffany Juarez,&nbsp;Richard B Lanman,&nbsp;Victoria M Raymond,&nbsp;Minhdan Nguyen,&nbsp;Judy D Truong,&nbsp;Annie Heng,&nbsp;Jaya Gill,&nbsp;Marlon Saria,&nbsp;Sandeep C Pingle,&nbsp;Santosh Kesari","doi":"10.2217/cns-2018-0015","DOIUrl":"https://doi.org/10.2217/cns-2018-0015","url":null,"abstract":"<p><p><b>Aim:</b> Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. <b>Methods:</b> Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. <b>Results:</b> A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in <i>ERBB2, MET, EGFR</i> and others. <b>Conclusion:</b> Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"8 2","pages":"CNS34"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37042504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 106
Efficacy and safety of immune checkpoint blockade for brain metastases. 免疫检查点阻断治疗脑转移瘤的疗效和安全性。
CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-03-11 DOI: 10.2217/cns-2018-0018
Maya Harary, David A Reardon, J Bryan Iorgulescu
{"title":"Efficacy and safety of immune checkpoint blockade for brain metastases.","authors":"Maya Harary,&nbsp;David A Reardon,&nbsp;J Bryan Iorgulescu","doi":"10.2217/cns-2018-0018","DOIUrl":"https://doi.org/10.2217/cns-2018-0018","url":null,"abstract":"hepatocellular carcinoma,","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"8 2","pages":"CNS33"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37042597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. 贝伐单抗治疗复发性胶质瘤后的长期生存模式:一个病例系列。
CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-07-11 DOI: 10.2217/cns-2019-0007
Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
{"title":"Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.","authors":"Liang Yen Liu,&nbsp;Matthew S Ji,&nbsp;Nhung T Nguyen,&nbsp;Frances E Chow,&nbsp;Donna M Molaie,&nbsp;Sean T Pianka,&nbsp;Richard M Green,&nbsp;Linda M Liau,&nbsp;Benjamin M Ellingson,&nbsp;Phioanh L Nghiemphu,&nbsp;Timothy F Cloughesy,&nbsp;Albert Lai","doi":"10.2217/cns-2019-0007","DOIUrl":"https://doi.org/10.2217/cns-2019-0007","url":null,"abstract":"<p><p><b>Aim:</b> Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). <b>Patients & methods:</b> We identified Bev-LTS as patients with post-Bev initiation survival times of ≥3 years among 1397 Bev treated recurrent glioma patients. <b>Results:</b> Among 962 grade-IV, 221 grade III, and 214 grade II Bev-treated glioma patients, we identified 28 (2.9%), 14 (6.3%) and 8 (3.7%) Bev-LTS patients, respectively. 45 Bev-LTS patients recurred on Bev, with 36 of those patients continuing therapy. <b>Conclusion:</b> Our study shows that a small portion of grade-IV, -III, and -II glioma patients can have long-term survival on Bev therapy even after Bev recurrence.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"8 2","pages":"CNS35"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2019-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37406325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信